NASDAQ:AMED Amedisys Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $116.32 +2.72 (+2.39%) (As of 07/7/2022 12:04 PM ET) Add Compare Share Today's Range$113.65▼$117.3950-Day Range$105.12▼$131.8952-Week Range$101.61▼$276.21Volume8,412 shsAverage Volume533,645 shsMarket Capitalization$3.79 billionP/E Ratio20.02Dividend YieldN/APrice Target$170.44 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amedisys MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside47.4% Upside$170.44 Price TargetShort InterestHealthy4.01% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.40Based on 5 Articles This WeekInsider TradingSelling Shares$64,055 Sold Last QuarterProj. Earnings Growth15.50%From $5.29 to $6.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.3.08 out of 5 starsMedical Sector10th out of 1,433 stocksHome Health Care Services Industry1st out of 9 stocks 4.3 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 10 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $170.44, Amedisys has a forecasted upside of 47.4% from its current price of $115.63.Amount of Analyst CoverageAmedisys has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.01% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amedisys has recently decreased by 14.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 2.4 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amedisys this week, compared to 4 articles on an average week.Search Interest2 people have searched for AMED on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,055.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amedisys is held by insiders.Percentage Held by Institutions90.47% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 15.50% in the coming year, from $5.29 to $6.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is 19.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 95.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is 19.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 73.92.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address About Amedisys (NASDAQ:AMED) StockAmedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More AMED Stock News HeadlinesJuly 6, 2022 | finance.yahoo.comAmedisys Announces Second Quarter 2022 Earnings Release and Conference Call Date - Yahoo FinanceJuly 6, 2022 | finance.yahoo.comAmedisys Announces Second Quarter 2022 Earnings Release and Conference Call DateJuly 7, 2022 | Investing Daily (Ad)Former Lawyer Went From $50K To $5.3M Trading OptionsSlaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M July 4, 2022 | benzinga.comU.S. Care Services Market Report 2022, Featuring Profiles of Kindred Healthcare, Amedisys, Sunrise Senior - BenzingaJuly 2, 2022 | finance.yahoo.comAmedisys, Inc.'s (NASDAQ:AMED) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?June 30, 2022 | seekingalpha.comADUS, AMED stocks given opposing views at Stifel on Medicare rate cuts (NASDAQ:AMED) - Seeking AlphaJune 30, 2022 | americanbankingnews.comInsider Selling: Amedisys, Inc. (NASDAQ:AMED) Insider Sells $64,055.00 in StockJune 30, 2022 | americanbankingnews.comJefferies Financial Group Reiterates "Buy" Rating for Amedisys (NASDAQ:AMED)July 7, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! June 29, 2022 | americanbankingnews.comAmedisys (NASDAQ:AMED) Now Covered by Analysts at Stifel NicolausJune 28, 2022 | streetinsider.comUPDATE: Stifel Starts Amedisys (AMED) at Hold - StreetInsider.comJune 28, 2022 | finance.yahoo.comAmedisys' (AMED) New Tie Up to Boost At-Home Patient CareJune 25, 2022 | americanbankingnews.comAnalysts Set Amedisys, Inc. (NASDAQ:AMED) PT at $173.27June 25, 2022 | americanbankingnews.comQ1 2023 EPS Estimates for Amedisys, Inc. Cut by Analyst (NASDAQ:AMED)June 24, 2022 | streetinsider.comMemorial Hermann and Contessa Partner to Provide Patients New At-Home Care Options - StreetInsider.comJune 24, 2022 | globenewswire.comMemorial Hermann and Contessa Partner to Provide Patients New At-Home Care Options - GlobeNewswireJune 24, 2022 | finance.yahoo.comMemorial Hermann and Contessa Partner to Provide Patients New At-Home Care OptionsJune 24, 2022 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Expected to Post Q3 2023 Earnings of $1.45 Per ShareJune 23, 2022 | americanbankingnews.comAmedisys (NASDAQ:AMED) PT Lowered to $125.00June 23, 2022 | americanbankingnews.comAmedisys (NASDAQ:AMED) Price Target Cut to $175.00June 23, 2022 | americanbankingnews.comAmedisys (NASDAQ:AMED) Lowered to Underperform at Bank of AmericaJune 23, 2022 | americanbankingnews.comAmedisys (NASDAQ:AMED) Sets New 1-Year Low After Analyst DowngradeJune 22, 2022 | americanbankingnews.comAmedisys (NASDAQ:AMED) Price Target Cut to $175.00 by Analysts at Truist FinancialJune 22, 2022 | americanbankingnews.comAmedisys (NASDAQ:AMED) Given New $107.00 Price Target at SVB LeerinkJune 21, 2022 | seekingalpha.comAmedisys stock slumps 13% as Bofa trims rating on CMS Medicare home health rate cut plans - Seeking AlphaJune 21, 2022 | seekingalpha.comConvey, Valneva top healthcare gainers; ACADIA, Comera Life lead losers' pack - Seeking AlphaJune 21, 2022 | benzinga.comDeutsche Bank Maintains Buy on Amedisys, Lowers Price Target to $175 - Benzinga - BenzingaSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees21,000Year Founded1982Company Calendar Last Earnings4/27/2022Today7/07/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$170.44 High Stock Price Forecast$213.00 Low Stock Price Forecast$102.00 Forecasted Upside/Downside+46.5%Consensus RatingModerate Buy Rating Score (0-4)2.5625 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$5.81 Trailing P/E Ratio20.02 Forward P/E Ratio21.99 P/E Growth2.26Net Income$209.07 million Net Margins8.59% Pretax Margin11.51% Return on Equity19.37% Return on Assets10.14% Debt Debt-to-Equity Ratio0.42 Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$2.21 billion Price / Sales1.71 Cash Flow$8.30 per share Price / Cash Flow14.02 Book Value$29.95 per share Price / Book3.88Miscellaneous Outstanding Shares32,570,000Free Float31,889,000Market Cap$3.79 billion OptionableOptionable Beta0.90 Social Links Amedisys Frequently Asked Questions Should I buy or sell Amedisys stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 1 sell rating, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amedisys stock. View analyst ratings for Amedisys or view top-rated stocks. What is Amedisys' stock price forecast for 2022? 16 brokers have issued 1-year price objectives for Amedisys' shares. Their AMED stock forecasts range from $102.00 to $213.00. On average, they predict Amedisys' share price to reach $170.44 in the next twelve months. This suggests a possible upside of 45.3% from the stock's current price. View analysts' price targets for Amedisys or view top-rated stocks among Wall Street analysts. How has Amedisys' stock performed in 2022? Amedisys' stock was trading at $161.88 at the beginning of the year. Since then, AMED stock has decreased by 27.5% and is now trading at $117.29. View the best growth stocks for 2022 here. When is Amedisys' next earnings date? Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Amedisys. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings data on Wednesday, April, 27th. The health services provider reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.12. The health services provider had revenue of $545.26 million for the quarter, compared to analysts' expectations of $557.81 million. Amedisys had a trailing twelve-month return on equity of 19.37% and a net margin of 8.59%. During the same quarter in the prior year, the business earned $1.54 earnings per share. View Amedisys' earnings history. How will Amedisys' stock buyback program work? Amedisys announced that its Board of Directors has approved a share repurchase plan on Wednesday, August 4th 2021, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its shares are undervalued. What guidance has Amedisys issued on next quarter's earnings? Amedisys updated its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share guidance of $5.23-$5.45 for the period, compared to the consensus EPS estimate of $5.33. The company issued revenue guidance of $2.330-$2.365 billion, compared to the consensus revenue estimate of $2.36 billion. Who are Amedisys' key executives? Amedisys' management team includes the following people: Mr. Christopher T. Gerard, CEO, Pres & Director (Age 55, Pay $872.7k) (LinkedIn Profile)Mr. Scott G. Ginn, Exec. VP & CFO (Age 53, Pay $779.31k) (LinkedIn Profile)Mr. David L. Kemmerly, Chief Legal & Gov. Affairs Officer (Age 59, Pay $547.27k) (LinkedIn Profile)Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations SystemsMr. Michael P. North, Chief Information Officer (Age 57) (LinkedIn Profile)Ms. Denise Bohnert, Chief Compliance Officer (Age 44) (LinkedIn Profile)Kendra Kimmons, VP of Marketing & Communications & Media RelationsMs. Megan Ambers, Interim Chief HR OfficerMr. John Nugent, Chief Acquisitions OfficerMs. Janet Britt, Sr. VP of Billing & Collections What is Paul B. Kusserow's approval rating as Amedisys' CEO? 297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees. Who are some of Amedisys' key competitors? Some companies that are related to Amedisys include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), R1 RCM (RCM), LHC Group (LHCG), AMN Healthcare Services (AMN), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY) and Cross Country Healthcare (CCRN). View all of AMED's competitors. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). What is Amedisys' stock symbol? Amedisys trades on the NASDAQ under the ticker symbol "AMED." How do I buy shares of Amedisys? Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amedisys' stock price today? One share of AMED stock can currently be purchased for approximately $117.29. How much money does Amedisys make? Amedisys (NASDAQ:AMED) has a market capitalization of $3.82 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $5.81 on an earnings per share basis. How many employees does Amedisys have? Amedisys employs 21,000 workers across the globe. When was Amedisys founded? Amedisys was founded in 1982. How can I contact Amedisys? Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for Amedisys is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163. This page (NASDAQ:AMED) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
